SOPHiA GENETICS CLO granted options and RSUs
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported equity awards consisting of new options and restricted stock units tied to ordinary shares.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported equity awards consisting of new options and restricted stock units tied to ordinary shares. The filing shows a grant of share options to purchase 142,216 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. A separate award granted 97,536 ordinary shares in the form of restricted stock units, with 25% of both the RSUs and options vesting on April 2, 2027 and the remainder vesting in installments through April 2, 2030. After these awards, Van Well is shown as beneficially owning 358,774 ordinary shares. This Form 4/A amends a prior report to correct the post-transaction ordinary share balance, which had been understated.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 239,752 shares
Grant/Award
2 txns
Insider
Van Well Daan
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 142,216 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 97,536 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 142,216 contracts (Direct);
Ordinary Shares — 358,774 shares (Direct)
Footnotes (3)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 97,536 ordinary shares due to an inadvertent error. The correct amount is 358,774 ordinary shares.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Share options granted: 142,216 options
Option exercise price: $5.04 per share
RSU shares granted: 97,536 RSUs
+4 more
7 metrics
Share options granted
142,216 options
Right to buy ordinary shares at $5.04, granted April 2, 2026
Option exercise price
$5.04 per share
Exercise price for 142,216 share options expiring April 2, 2036
RSU shares granted
97,536 RSUs
Restricted stock units representing ordinary shares, granted April 2, 2026
Shares owned after grant
358,774 ordinary shares
Amount of securities beneficially owned following reported transactions
RSU vesting start
April 2, 2027
25% of RSUs vest on this date; remainder quarterly to April 2, 2030
Option vesting start
April 2, 2027
25% of options vest then, remaining monthly to April 2, 2030
Option expiration
April 2, 2036
Expiration date of granted share options if unexercised
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, contingent right to receive one ordinary share, vest, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity awards did SOPHiA GENETICS (SOPH) report for Daan Van Well?
SOPHiA GENETICS reported that Chief Legal Officer Daan Van Well received share options for 142,216 ordinary shares and 97,536 restricted stock units. These compensation grants increase his equity exposure without any cash purchase, as both were granted at a reported price of $0.00 per share.
What are the vesting terms of Daan Van Well’s RSU grant at SOPHiA GENETICS (SOPH)?
The RSU grant of 97,536 ordinary shares vests 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. Each vested RSU entitles him to receive one ordinary share, contingent on continued service.
Why was this SOPHiA GENETICS (SOPH) Form 4/A filed as an amendment?
This Form 4/A corrects the number of ordinary shares beneficially owned after the reported transactions. The original Form 4 had inadvertently reported 97,536 ordinary shares; the amendment clarifies that the correct post-transaction amount is 358,774 ordinary shares held by Daan Van Well.
AI-generated analysis. How Rhea-AI works. Not financial advice.
